Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581657 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM
A Phase 2 study, sponsored by PhaseBio Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT02581657 is a Phase 2 study that has completed, run by PhaseBio Pharmaceuticals. The registered enrollment target is 37 participants.
The verdict
NCT02581657, a Phase 2 study, has completed, sponsored by PhaseBio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
This study is a randomized, double-blind (Investigator and study subject), placebo controlled multiple dose sequential ascending dose study that will enroll up to 47 male and female subjects with type 2 diabetes mellitus (T2DM) in up to four cohorts.
Interventions
- DRUG Placebo Injection
- DRUG PE0139 Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02581657
The ClinicalTrials.gov registry entry for NCT02581657 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PhaseBio Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Injection is the first listed.
NCT02581657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02581657 about?
NCT02581657 is a clinical study titled "Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM". This study is a randomized, double-blind (Investigator and study subject), placebo controlled multiple dose sequential ascending dose study that will enroll up to 47 male and female subjects with type 2 diabetes mellitus (T2DM) in up to four cohorts.
What is the current status of trial NCT02581657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2015-10. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02581657?
The interventions under investigation include: Placebo Injection (DRUG), PE0139 Injection (DRUG).
Who is sponsoring clinical trial NCT02581657?
This trial is sponsored by PhaseBio Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.